视网膜色素变性治疗循证指南(2021年)  

Clinical evidenced guideline for treatment of retinitis pigmentosa

作　　者：中国眼科遗传联盟中国眼遗传病诊疗小组中国医师协会眼科医师分会遗传眼病学组 金子兵 Chinese Eye Genetics Consortium,Chinese Team for Clinical Diagnosis and Treatment of Genetic Eye Diseases,Genetic Eye Disease Group,Ophthalmologist Branch,Chinese Medical Doctor Association

机构地区：[1]不详

出　　处：《眼科》2021年第4期249-258,共10页Ophthalmology in China

摘　　要：视网膜色素变性(retinitis pigmentosa,RP)是眼科常见的遗传性视网膜疾病,常合并眼部多种并发症。针对RP原发病治疗的报道较多,包括药物、激光、手术治疗以及基因治疗和细胞治疗等。既往的治疗方法大多疗效不明确,而近期发展的某些基因治疗和细胞治疗方法经临床试验证实了其安全性,可改善部分患者视功能,值得进行大规模随机对照临床试验研究。此外,RP合并白内障等眼部并发症的治疗也存在较多问题。本指南参考一些文献和广泛征求有关专家的意见对RP原发病及眼部常见并发症的治疗进行总结,供眼科医师参考。Retinitis pigmentosa(RP)is the most common hereditary retinal disease.There are many reports on the treatment of RP,including the drugs,laser,surgical,gene and cell therapy.The effectiveness of previous treatments is ambiguous.The emerging gene therapy and cell therapy for RP have shown safety and worth further investigations and randomized clinical trials.In addition,there are some problems in the treatment of RP combined with cataract and other ocular complications.This guideline summarizes treatments of RP and its complications,refers to the latest literatures,and extensively solicits opinions from experts for the reference of ophthalmologists.(Ophthalmol CHN,2021,30:249-258)

关 键 词：视网膜色素变性/治疗 循证指南 

分 类 号：R73[医药卫生—肿瘤]